2026-09-19T13:07:15Zhttps://wakespace.lib.wfu.edu/server/oai/request

oai:null:10339/361642026-09-18T13:36:12Zcom_10339_14934col_10339_38132

Jordan, Jennifer Hawthorne 2011-09-08T08:36:06Z 2013-09-08T08:30:10Z 2011 https://wakespace.lib.wfu.edu/handle/10339/36164 Anthracycline chemotherapies induce nonfocal cardiac injury to the left ventricular (LV) myocardium. This damage, chemotherapy induced cardiotoxicity, is difficult to detect noninvasively prior to the advancement of injury to an irreversible state with decrements in left ventricular ejection fraction (LVEF). As cancer survival rates increase, the occurrence of chemotherapy induced cardiotoxicity is also increasing with reports of chronic heart failure rates of 3-36%, dependent on total dosage of chemotherapy. The recognition of the need to better manage the cardiovascular care of oncology patients and survivors of cancer has necessitated an emerging field, cardio-oncology, to bring the two areas of clinical practice together. The current noninvasive method of detecting cardiotoxicity, a decrement in LVEF, may occur before the extent of myocardial injury is irreversible. Safe, noninvasive methods for accurately detecting early evidence of myocardial injury are critically needed to prevent irreversible cardiotoxicity. en Wake Forest University Cardiotoxicity Cardiovascular Chemotherapy Imaging Magnetic Resonance Early Identification of Chemotherapy Induced Cardiotoxicity Using Structural and Functional Cardiovascular MRI Dissertation Hamilton, Craig A Hundley, William G Kraft, Robert A Plemmons, Robert J Santago II, Peter Biomedical Engineering 2013-09-08 restricted